Loading
Loading
Research Overview
D-retro-inverso stapled peptide that disrupts the FOXO4–p53 protein interaction in senescent cells; this interaction normally keeps senescent cells alive by blocking p53-mediated apoptosis — disrupting it restores apoptotic sensitivity in senescent cells specifically.
FOXO4-DRI is a synthetically engineered peptide developed for use in preclinical research focused on cellular aging and senescence. Unlike naturally occurring peptides, FOXO4-DRI is designed to interfere with specific protein-protein interactions—particularly those involving the transcription factor FOXO4 and the tumor suppressor protein p53. These interactions are believed to play a role in the survival of senescent cells, which accumulate over time and are commonly studied in relation to aging processes in controlled laboratory environments.
In experimental models, FOXO4-DRI has been investigated for its potential senolytic activity—meaning its ability to selectively target and influence senescent cells without affecting normal, healthy cells. Research has explored how disrupting the FOXO4–p53 interaction may trigger pathways associated with programmed cell death (apoptosis) in these aged or damaged cells. This line of study is particularly relevant in understanding how cellular clearance mechanisms may contribute to tissue homeostasis and age-related biological changes.
Across in vitro and animal-based studies, FOXO4-DRI has been examined for its potential effects on various biological systems, including those associated with tissue regeneration, inflammation, and cellular stress responses. Investigations often focus on how the peptide may influence signaling pathways linked to DNA damage responses, oxidative stress, and cellular repair processes. These studies aim to better understand how senescent cell accumulation impacts overall biological function and how targeted interventions might modulate these effects.
To support consistent experimental outcomes, FOXO4-DRI is synthesized and modified for stability in laboratory settings, allowing for controlled analysis of its molecular behavior and interactions. All findings related to FOXO4-DRI are derived exclusively from non-clinical research. There are currently no established conclusions regarding its safety, pharmacokinetics, dosing, or therapeutic applications in humans, and all observations remain within the scope of ongoing scientific investigation.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, foxo4-dri peptide has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
FOXO4-DRI Peptide research is most relevant to protocols examining:
Senolytic research targeting clearance of senescent cells
FOXO4–p53 protein interaction and apoptosis pathway studies
Healthspan and longevity research via cellular senescence reduction
Researchers studying stapled peptide technology in vivo
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Downstream biological effects become detectable. Key biomarkers worth monitoring from this point.
Peak activity window
Effects compound in this window. Given limited human data, careful documentation is important.
Washout & review
Allow full washout (~5× half-life: ~Hours). Review data, confirm baseline recovery before any repeat protocol.
D-retro-inverso stapled peptide that disrupts the FOXO4–p53 protein interaction in senescent cells; this interaction normally keeps senescent cells alive by blocking p53-mediated apoptosis — disrupting it restores apoptotic sensitivity in senescent cells specifically.
| Parameter | Value |
|---|---|
| Dose range | 5 mg/kg (preclinical |
| Alt. dose 2 | human dosing undefined) |
| Schedule | Pulsed / intermittent |
| Route | Subcutaneous, Intravenous |
| Half-life | ~Hours |
highly experimental
Available from Capital Peptides
References
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.